OBJECTIVES: To determine mechanisms involved in @entity409 ( @entity409 ) during the course of @entity625 and to investigate the link between cytokines, chemokines and @entity9249 . APPROACH AND RESULTS: Experiments were conducted on aortic rings at day 4 (preclinical), day 11 (onset of disease), day 33 ( @entity697 ) and day 90 ( @entity102 ) after adjuvant-induced @entity625 (AIA) in Lewis @entity35 . At day 4, the @entity455 was a reduced @entity1063 -induced @entity15496 . At day 11, endothelial function assessed by the relaxation to @entity934 was normal despite increased @entity4645 activity (COX-2) and overproduction of @entity224 anions that was compensated by increased @entity842 synthase (NOS) activity. At day 33, @entity409 apparition coincides with the normalization of NOS activity. At day 90, @entity409 was only observed in @entity35 with a persisting imbalance between endothelial NOS and COX-2 pathways and higher plasma levels of @entity3426 and @entity1505 . Plasma levels of @entity3426 , @entity1505 and @entity9269 negatively correlated with Ach-induced relaxation throughout the course of AIA. CONCLUSIONS: Our data identified increased endothelial NOS activity as an important compensatory response that opposes the @entity409 in the early @entity625 . Thereafter, a cross-talk between endothelial COX-2/NOS pathways appears as an important element for the occurrence of @entity409 . Our results encourage determining the clinical value of @entity3426 , @entity1505 and @entity9269 as biomarkers of @entity409 in @entity309 .

Endothelial Dysfunction in XXXX : Mechanistic Insights and Correlation with Circulating Markers of Systemic Inflammation.

@entity9269 :: ('25542(Tax:10116)', 'Gene') :: ['MIP-1a'] @entity697 :: ('MESH:D000208', 'Disease') :: ['acute disease'] @entity455 :: ('MESH:D014652', 'Disease') :: ['unique vascular abnormality'] @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis'] @entity9249 :: ('25341(Tax:10116)', 'Gene') :: ['osteoprotegerin'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction', 'ED'] @entity1505 :: ('24835(Tax:10116)', 'Gene') :: ['TNFa'] @entity4645 :: ('29527(Tax:10116)', 'Gene') :: ['cyclo-oxygenase-2'] @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic disease'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity224 :: ('MESH:D013481', 'Chemical') :: ['superoxide'] @entity3426 :: ('24494(Tax:10116)', 'Gene') :: ['IL-1b'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine'] @entity309 :: ('MESH:D001172', 'Disease') :: ['RA'] @entity15496 :: ('MESH:D015877', 'Disease') :: ['constriction'] @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']
@entity309 :: (MESH:D001172,Disease) :: ['Rheumatoid Arthritis']
